Regeneron Pharmaceuticals, Inc. (REGN)
827.72
-15.75
(-1.87%)
USD |
NASDAQ |
Sep 04, 16:00
828.01
+0.29
(+0.04%)
After-Hours: 20:00
Regeneron Pharmaceuticals Research and Development Expense (Quarterly) : 1.508B for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.508B |
| March 31, 2026 | 1.420B |
| December 31, 2025 | 1.481B |
| September 30, 2025 | 1.338B |
| June 30, 2025 | 1.287B |
| March 31, 2025 | 1.200B |
| December 31, 2024 | 1.272B |
| September 30, 2024 | 1.150B |
| June 30, 2024 | 1.079B |
| March 31, 2024 | 1.134B |
| December 31, 2023 | 1.051B |
| September 30, 2023 | 969.90M |
| June 30, 2023 | 982.20M |
| March 31, 2023 | 1.002B |
| December 31, 2022 | 941.60M |
| September 30, 2022 | 818.70M |
| June 30, 2022 | 719.90M |
| March 31, 2022 | 769.50M |
| December 31, 2021 | 711.10M |
| September 30, 2021 | 592.20M |
| June 30, 2021 | 643.10M |
| March 31, 2021 | 675.50M |
| December 31, 2020 | 682.80M |
| September 30, 2020 | 625.30M |
| June 30, 2020 | 663.20M |
| Date | Value |
|---|---|
| March 31, 2020 | 527.80M |
| December 31, 2019 | 498.10M |
| September 30, 2019 | 473.10M |
| June 30, 2019 | 833.40M |
| March 31, 2019 | 435.10M |
| December 31, 2018 | 558.44M |
| September 30, 2018 | 521.53M |
| June 30, 2018 | 495.65M |
| March 31, 2018 | 462.23M |
| December 31, 2017 | 493.48M |
| September 30, 2017 | 492.03M |
| June 30, 2017 | 474.85M |
| March 31, 2017 | 469.32M |
| December 31, 2016 | 450.31M |
| September 30, 2016 | 515.21M |
| June 30, 2016 | 534.90M |
| March 31, 2016 | 447.14M |
| December 31, 2015 | 438.30M |
| September 30, 2015 | 405.25M |
| June 30, 2015 | 375.03M |
| March 31, 2015 | 327.09M |
| December 31, 2014 | 337.61M |
| September 30, 2014 | 323.72M |
| June 30, 2014 | 281.48M |
| March 31, 2014 | 275.85M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| AbbVie, Inc. | 2.344B |
| Gilead Sciences, Inc. | 1.69B |
| Amgen, Inc. | 1.868B |
| Biogen, Inc. | 461.70M |